Compare CHGA & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGA | CMND |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.6M |
| IPO Year | 2015 | 2021 |
| Metric | CHGA | CMND |
|---|---|---|
| Price | $0.22 | $1.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 278.7K | 138.5K |
| Earning Date | N/A | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.07 |
| 52 Week High | $0.24 | $4.66 |
| Indicator | CHGA | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 51.33 |
| Support Level | $0.18 | $1.74 |
| Resistance Level | $0.23 | $2.25 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 65.75 | 89.15 |
Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.